Journal
CLINICAL PHARMACOLOGY & THERAPEUTICS
Volume 97, Issue 5, Pages 447-450Publisher
WILEY
DOI: 10.1002/cpt.91
Keywords
-
Categories
Funding
- NCI NIH HHS [R21 CA170063, U10 CA180870, U10 CA180833, U24 CA196171] Funding Source: Medline
Ask authors/readers for more resources
The identification of druggable molecular alterations represents one of the greatest advances in cancer treatment. Such progress is particularly evident for lung cancer, which now has numerous molecularly defined subsets such as epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements. However, understanding of the significance of these genomic alterations is largely limited to incurable, metastatic lung cancer. ALCHEMIST (Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial) is a National Cancer Institute-sponsored initiative to address these questions in earlier-stage disease.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available